Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
CardioVascular and Interventional Radiology
Erschienen in: CardioVascular and Interventional Radiology 2/2016

01.02.2016 | Review

Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 2, Insights into the Technical Rationale

verfasst von: Fei Sun, Verónica Crisóstomo, Claudia Báez-Díaz, Francisco M. Sánchez

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Rationale of prostatic artery embolization (PAE) in the treatment of symptomatic benign prostatic hyperplasia is conventionally believed to include two parts: shrinkage of the enlarged prostate gland as a result of PAE-induced ischemic infarction and potential effects to relax the increased prostatic smooth muscle tone by reducing the number and density of α1-adrenergic receptor in the prostate stroma. This review describes new insights into the likely mechanisms behind PAE, such as ischemia-induced apoptosis, apoptosis enhanced by blockage of androgens circulation to the embolized prostate, secondary denervation following PAE, and potential effect of nitric oxide pathway immediately after embolization. Studies on therapeutic mechanisms in PAE may shed light on potentially new treatment strategies and development of novel techniques.
Literatur
1.
Smith JC Jr, Kerr WS, Athanasoulis CA, Waltman AC, Ring EJ, Baum S. Angiographic management of bleeding secondary to genitourinary tract surgery. J Urol. 1975;113(1):89–92.PubMed
2.
Mitchell ME, Waltman AC, Athanasoulis CA, Kerr WS Jr, Dretler SP. Control of massive prostatic bleeding with angiographic techniques. J Urol. 1976;115(6):692–5.PubMed
3.
Hare WS, Holland CJ. Paresis following internal iliac artery embolization. Radiology. 1983;146(1):47–51.CrossRefPubMed
4.
Appleton DS, Sibley GN, Doyle PT. Internal iliac artery embolisation for the control of severe bladder and prostate haemorrhage. Br J Urol. 1988;61(1):45–7.CrossRefPubMed
5.
Pisco JM, Martins JM, Correia MG. Internal iliac artery: embolization to control hemorrhage from pelvic neoplasms. Radiology. 1989;172(2):337–9.CrossRefPubMed
6.
Delgal A, Cercueil JP, Koutlidis N, Michel F, Kermarrec I, Mourey E, Cormier L, Krausé D, Loffroy R. Outcome of transcatheter arterial embolization for bladder and prostate hemorrhage. J Urol. 2010;183(5):1947–53.CrossRefPubMed
7.
Loffroy R, Pottecher P, Cherblanc V, Favelier S, Estivalet L, Koutlidis N, Moulin M, Cercueil JP, Cormier L, Krausé D. Current role of transcatheter arterial embolization for bladder and prostate hemorrhage. Diagn Interv Imaging. 2014;95(11):1027–34.CrossRefPubMed
8.
Jander HP, Russinovich NA. Transcatheter gelfoam embolization in abdominal, retroperitoneal, and pelvic hemorrhage. Radiology. 1980;136(2):337–44.CrossRefPubMed
9.
DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol. 2000;11(6):767–70.CrossRefPubMed
10.
Sun F, Sánchez FM, Crisóstomo V, Lima JR, Luis L, García-Martínez V, López-Sánchez C, Usón J, Maynar M. Benign prostatic hyperplasia: transcatheter arterial embolization as potential treatment-preliminary study in pigs. Radiology. 2008;246(3):783–9.CrossRefPubMed
11.
Mauro MA. Can hyperplastic prostate follow uterine fibroids and be managed with transcatheter arterial embolization? Radiology. 2008;246(3):657–8.CrossRefPubMed
12.
Faintuch S, Mostafa EM, Carnevale FC, Ganguli S, Rabkin DJ, Goldberg SN. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia in a canine model (abstract). J Vasc Interv Radiol. 2008;19(2):S1–210.CrossRef
13.
Carnevale FC, Antunes AA, da Motta Leal Filho JM, de Oliveira Cerri LM, Baroni RH, Marcelino AS, Freire GC, Moreira AM, Srougi M, Cerri GG. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol. 2010;33(2):355–61.PubMedCentralCrossRefPubMed
14.
Pisco JM, Pinheiro LC, Bilhim T, Duarte M, Mendes JR, Oliveira AG. Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol. 2011;22(1):11–9.CrossRefPubMed
15.
McWilliams JP, Kuo MD, Rose SC, Bagla S, Caplin DM, Cohen EI, Faintuch S, Spies JB, Saad WE, Nikolic B. Society of interventional radiology position statement: prostate artery embolization for treatment of benign disease of the prostate. J Vasc Interv Radiol. 2014;25(9):1349–51.CrossRefPubMed
16.
Stokes LS, Wallace MJ, Godwin RB, Kundu S, Cardella JF, Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomas. J Vasc Interv Radiol. 2010;21(8):1153–63.CrossRefPubMed
17.
Drooz AT, Lewis CA, Allen TE, Citron SJ, Cole PE, Freeman NJ, Husted JW, Malloy PC, Martin LG, Van Moore A, Neithamer CD, Roberts AC, Sacks D, Sanchez O, Venbrux AC, Bakal CW, Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for percutaneous transcatheter embolization. J Vasc Interv Radiol. 2003;14(9):S237–42.PubMed
18.
Camara-Lopes G, Mattedi R, Antunes AA, Carnevale FC, Cerri GG, Srougi M, Alves VA, Leite KR. The histology of prostate tissue following prostatic artery embolization for the treatment of benign prostatic hyperplasia. Int Braz J Urol. 2013;39(2):222–7.PubMed
19.
Pisco J, Campos Pinheiro L, Bilhim T, Duarte M, Rio Tinto H, Fernandes L, Vaz Santos V, Oliveira AG. Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results. Radiology. 2013;266(2):668–77.CrossRefPubMed
20.
Carnevale FC, da Motta-Leal-Filho JM, Antunes AA, Baroni RH, Marcelino AS, Cerri LM, Yoshinaga EM, Cerri GG, Srougi M. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol. 2013;24(4):535–42.CrossRefPubMed
21.
Bagla S, Martin CP, van Breda A, Sheridan MJ, Sterling KM, Papadouris D, Rholl KS, Smirniotopoulos JB, van Breda A. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014;25(1):47–52.CrossRefPubMed
22.
Brook OR, Faintuch S, Brook A, Goldberg SN, Rofsky NM, Lenkinski RE. Embolization therapy for benign prostatic hyperplasia: influence of embolization particle size on gland perfusion. J Magn Reson Imaging. 2013;38(2):380–7.CrossRefPubMed
23.
Bilhim T, Pisco J, Pinheiro LC, Tinto HR, Fernandes L, Pereira JA, Duarte M, Oliveira AG. Does polyvinyl alcohol particle size change the outcome of prostatic arterial embolization for benign prostatic hyperplasia? Results from a single-center randomized prospective study. J Vasc Interv Radiol. 2013;24(11):1595–602.CrossRefPubMed
24.
Wang MQ, Guo LP, Zhang GD, Yuan K, Li K, Duan F, Yan JY, Wang Y, Kang HY, Wang ZJ. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. BMC Urol. 2015;15:33.PubMedCentralCrossRefPubMed
25.
Kurbatov D, Russo GI, Lepetukhin A, Dubsky S, Sitkin I, Morgia G, Rozhivanov R, Cimino S, Sansalone S. Prostatic artery embolization for prostate volume greater than 80 cm3: results from a single-center prospective study. Urology. 2014;84(2):400–4.CrossRefPubMed
26.
de Assis AM, Moreira AM, de Paula Rodrigues VC, Yoshinaga EM, Antunes AA, Harward SH, Srougi M, Carnevale FC. Prostatic artery embolization for treatment of benign prostatic hyperplasia in patients with prostates >90 g: a prospective single-center study. J Vasc Interv Radiol. 2015;26(1):87–93.CrossRefPubMed
27.
Golzarian J, Weng L. Particle embolization: factors affecting arterial distribution. J Vasc Interv Radiol. 2014;25(11):1773–4.CrossRefPubMed
28.
Ofjord ES, Clausen G. Intrarenal flow of microspheres and red blood cells: skimming in slit and tube models. Am J Physiol. 1983;245(3):H429–36.PubMed
29.
Bilhim T, Pisco JM, Tinto HR, Fernandes L, Pinheiro LC, Furtado A, Casal D, Duarte M, Pereira J, Oliveira AG, O’Neill JE. Prostatic arterial supply: anatomic and imaging findings relevant for selective arterial embolization. J Vasc Interv Radiol. 2012;23(11):1403–15.CrossRefPubMed
30.
Carnevale FC, Moreira AM, Antunes AA. The “PErFecTED technique”: proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2014;37(6):1602–5.CrossRefPubMed
31.
Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, Fracchia JA. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003;169(1):20–3.CrossRefPubMed
32.
Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Silverio FD. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide. J Androl. 1997;18(5):488–94.PubMed
33.
Bilhim T. Response to “does polyvinyl alcohol particle size change the outcome of prostatic arterial embolization for benign prostatic hyperplasia? Results from a single-center randomized prospective study”. J Vasc Interv Radiol. 2014;25(4):659–60.CrossRefPubMed
34.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57.PubMedCentralCrossRefPubMed
35.
Haanen C, Vermes I. Apoptosis and inflammation. Mediat Inflamm. 1995;4(1):5–15.CrossRef
36.
Lekås E, Engstrand C, Bergh A, Damber JE. Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res. 1999;27(3):174–9.CrossRefPubMed
37.
Lekås E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res. 1997;25(5):309–14.CrossRefPubMed
38.
Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate. 1998;36(3):201–6.CrossRefPubMed
39.
Franck-Lissbrant I, Häggström S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology. 1998;139(2):451–6.PubMed
40.
Sun F, Sánchez FM, Crisóstomo V, Díaz-Güemes I, López-Sánchez C, Usón J, Maynar M. Transarterial prostatic embolization: initial experience in a canine model. Am J Roentgenol. 2011;197(2):495–501.CrossRef
41.
Frenk NE, Baroni RH, Carnevale FC, Gonçalves OM, Antunes AA, Srougi M, Cerri GG. MRI findings after prostatic artery embolization for treatment of benign hyperplasia. Am J Roentgenol. 2014;203(4):813–21.CrossRef
42.
Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4 Suppl 1):2–7.CrossRefPubMed
43.
Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol. 1999;161(1):332–7.CrossRefPubMed
44.
45.
Uygur MC, Arik AI, Altuğ U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids. 1998;63(4):208–13.CrossRefPubMed
46.
Pisco JM, Tinto HR, Pinheiro LC, Bilhim T, Duarte M, Fernandes L, Pereira J, Oliveira AG. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol. 2013;23(9):2561.CrossRefPubMed
47.
Antunes AA, Carnevale FC, da Motta Leal Filho JM, Yoshinaga EM, Cerri LM, Baroni RH, Marcelino AS, Cerri GG, Srougi M. Clinical, laboratorial, and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia. A prospective single-center pilot study. Cardiovasc Intervent Radiol. 2013;36(4):978–86.CrossRefPubMed
48.
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–91.CrossRefPubMed
49.
Smith AB, Carson CC. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009;5(3):535–45.PubMedCentralPubMed
50.
Din KE, Kiemeney LALM, de Wildt MJ, Debruyne FM, de la Rosette JJ. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology. 1996;48(3):393–7.CrossRef
51.
Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 1993;150(2 Pt 1):351–8.PubMed
52.
Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol. 1993;150(6):2002–6.PubMed
53.
Nasu K, Moriyama N, Kawabe K, Tsujimoto G, Murai M, Tanaka T, Yano J. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol. 1996;119(5):797–803.PubMedCentralCrossRefPubMed
54.
Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol. 1982;128(4):836–9.PubMed
55.
Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64(6):1081–8.CrossRefPubMed
56.
Hennenberg M, Stief CG, Gratzke C. Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling. Neurourol Urodyn. 2014;33(7):1074–85.CrossRefPubMed
57.
Resnick MI, Roehrborn CG. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. Prostate Cancer Prostatic Dis. 2007;10(2):155–9.CrossRefPubMed
58.
Brehmer M, Hilliges M, Kinn AC. Denervation of periurethral prostatic tissue by transurethral microwave thermotherapy. Scand J Urol Nephrol. 2000;34(1):42–5.CrossRefPubMed
59.
Bdesha AS, Schachter M, Sever P, Witherow RO. Radioligand-binding analysis of human prostatic alpha-1 adrenoreceptor density following transurethral microwave therapy. Br J Urol. 1996;78(6):886–92.CrossRefPubMed
60.
Zlotta AR, Raviv G, Peny MO, Noel JC, Haot J, Schulman CC. Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. J Urol. 1997;157(3):894–9.CrossRefPubMed
61.
Hedlund P. Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract—is there a basis for pharmacological targeting of cGMP? World J Urol. 2005;23(6):362–7.CrossRefPubMed
62.
Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn. 2007;26(6 Suppl):934–47.CrossRefPubMed
63.
Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol. 2008;26(6):603–9.CrossRefPubMed
64.
Depré C, Fiérain L, Hue L. Activation of nitric oxide synthase by ischaemia in the perfused heart. Cardiovasc Res. 1997;33(1):82–7.CrossRefPubMed
65.
Malinski T, Bailey F, Zhang ZG, Chopp M. Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1993;13(3):355–8.CrossRefPubMed
66.
Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 1997;20(3):132–9.CrossRefPubMed
67.
Eliasson MJ, Huang Z, Ferrante RJ, Sasamata M, Molliver ME, Snyder SH, Moskowitz MA. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. J Neurosci. 1999;19(14):5910–8.PubMed
68.
Yalçinkaya FR, Davarci M, Akçin S, Gökçe A, Güven EO, İnci M, Balbay MD. Urodynamic evaluation of acute effects of sildenafil on voiding among males with erectile dysfunction and symptomatic benign prostate. Turk J Med Sci. 2012;42(6):951–6.
Metadaten
Titel
Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 2, Insights into the Technical Rationale
verfasst von
Fei Sun
Verónica Crisóstomo
Claudia Báez-Díaz
Francisco M. Sánchez
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 2/2016
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-015-1238-5

Weitere Artikel der Ausgabe 2/2016

CardioVascular and Interventional Radiology 2/2016 Zur Ausgabe

Clinical Investigation

Clinical Long-Term Outcome and Reinterventional Rate After Uterine Fibroid Embolization with Nonspherical Versus Spherical Polyvinyl Alcohol Particles

Technical Note

Transiliac Paraendograft Embolisation of Type 2 Endoleak: An Alternative Approach for Endoleak Management

Technical Note

Aorta Balloon Occlusion in Trauma: Three Cases Demonstrating Multidisciplinary Approach Already on Patient’s Arrival to the Emergency Room

Brief Communication

Proximal Embolization of the Splenic Artery with a Penumbra Occlusion Device (POD): A Novel Occlusion Technique for Blunt Splenic Injuries

Clinical Investigation

Renal Sympathetic Denervation by CT-Guided Ethanol Injection: A Phase II Pilot Trial of a Novel Technique

Clinical Investigation

Radiation Exposure in Transjugular Intrahepatic Portosystemic Shunt Creation

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet

29.03.2024 | Diagnostische Radiologie | Nachrichten

Studie bestätigt Potenzial von KI in der Radiologie

26.03.2024 | Koronare Herzerkrankung | Nachrichten

Quantitative Angiografie könnte IVUS-Alternative darstellen
weitere anzeigen

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen